We sought to determine the prevalence and patterns of complementary and alternative medicine (CAM) use among head and neck cancer patients who were being treated at an academic otolaryngology practice in the northeastern United States from January 2005 through December 2006. During a 3-month period, we conducted an anonymous survey of 213 new and established patients regarding their use of CAM during their cancer treatment. According to the responses, only 13 of these patients (6.1%) were currently using CAM during treatment. With respect to the various products being taken, 9 patients (69.2% of all CAM users) were taking herbs or supplements. Only 7 patients (53.8%) who used CAM disclosed this fact to their physician during in-offi ce encounters. The most common sources for obtaining CAM were health-food stores, where most patients spent approximately $25 per week. The most frequently cited reason for using CAM was that a particular product had been recommended by family or friends as being potentially helpful. No adverse effects of CAM were reported. We conclude that while CAM use was not very prevalent in this study, patients who did use it were employing modalities with biologic activity that may potentially interact with conventional therapies. Because patients' disclosure of CAM use is frequently not volunteered, otolaryngologists should routinely elicit this information in a highly specifi c fashion so that we may better serve our unique patient population.
Introduction
Complementary and alternative medicine (CAM) is defi ned by the National Institutes of Health's National Center for Complementary and Alternative Medicine (NCCAM) as "a group of diverse medical and healthcare systems, practices, and products that are not generally considered part of conventional medicine." 1 At the time of this survey, the NCCAM categorized CAM into fi ve distinct subclasses: alternative medical systems, biologically based therapies, mind-body interventions, manipulative and body-based treatments, and energy therapies. (Since then, the NCCAM has revised this classifi cation and now categorizes CAM into four subclasses: natural products, mind-body medicine, manipulative and body-based practices, and other. 1 ) The use of these products and practices is not typically taught in U.S. and European medical schools, and they are considered to be outside the mainstream of medical practice. While scientifi c evidence regarding a number of CAM therapies does exist, key questions about the safety and effi cacy of most of them remain to be answered through welldesigned scientifi c studies.
Despite these concerns, CAM continues to be popular. It is estimated that nearly 40% of the U.S. population currently uses at least one type of nontraditional medicine, and the numbers continue to rise. 2 Among oncology patients, CAM use may be even more widespread, as some studies have shown rates in excess of 90%. [3] [4] [5] [6] [7] However, there is a relative paucity of data regarding CAM use patterns among individuals with head and neck cancer. Indeed, most data concerning CAM use in this context are derived from larger series that included only a small subset of head and neck cancer patients. That these studies are heterogeneous and have inconsistent defi nitions of CAM makes it even more diffi cult to apply their fi ndings to our patient population.
While CAM use for head and neck cancer has been explored in European, Canadian, and Israeli patient groups, 8-10 its prevalence has not yet been fully elucidated among American patients, although there are some indications that CAM use in this particular population may actually be declining. Therefore, we undertook this study to evaluate patterns of the use of CAM (as defi ned by the NCCAM) among head and neck oncology patients in the United States.
Patients and methods
Over a 3-month period, new and established patients who had been treated at Thomas Jefferson University Hospital's Department of Otolaryngology-Head and Neck Surgery from January 2005 through December 2006 were asked to participate in an anonymous survey during outpatient visits. Each of these patients carried a diagnosis of epithelial or nonepithelial malignancy of the head and neck. Consenting patients were asked to complete a 12point questionnaire regarding CAM use. In addition to compiling information on basic demographics and each patient's principal diagnosis, we asked patients whether they had used any complementary or alternative therapies during the course of their treatment for head and neck cancer.
Those patients who responded positively were then asked to complete an additional 8-question survey specifi c to their use of CAM. These follow-up questions were directed toward ascertaining (1) the types of CAM used, (2) the factors that led each patient to pursue CAM, (3) the sources where patients obtained CAM, (4) their average weekly expenditure on CAM, (5) their perception of CAM's effi cacy in treating their cancer, (6) the number and severity of side effects they experienced while using CAM, (7) the tolerability of CAM compared with standard therapies, and (8) the extent to which patients discussed the use of CAM with their physicians and their perception of their physician's response to such use.
This study was undertaken in compliance with the guidelines set forth by and with the approval of the Thomas Jefferson University Hospital Division of Human Subjects Protection-Institutional Review Board.
Results
Over the 3-month survey period, 213 patients-144 men and 69 women (mean age: 61 yr; median: 60)-consented to participate and were included in the study. The most common diagnosis (n = 62 [29.1%]) was carcinoma of the oral cavity (fi gure 1).
Overall, 13 patients (6.1%) indicated that they used at least one CAM modality; 8 of them reported that they used more than one (some within the same subcategory). Of the fi ve NCCAM subcategories, the most commonly used (n = 9 [69.2% of CAM users]) were the biologically based therapies (fi gure 2). Megadose vitamins and herbal remedies were the most common products in this group. None of the respondents used alternative medical systems or energy therapies.
Patients who chose to use CAM most often did so because it had been suggested by family or friends as being potentially helpful (n = 7 [53.8% of CAM users]). Five patients (38.5%) used CAM because they felt that conventional medicine was by itself not able to adequately treat their cancer, although no patient cited dissatisfaction with conventional medical care as the primary reason for pursuing CAM. Two patients cited the Internet as the principal source of information related to their CAM use. Products related to CAM use were most frequently obtained at health food stores. Most patients spent approximately $25 per a week on CAM.
No patient reported any side effects related to CAM use. Indeed, all patients stated that their CAM therapy was as tolerable as or better tolerated than their conventional cancer treatments.
All 13 CAM users said that they undertook their CAM use with the expectation that it would cure them rather than just improve their general well-being. Seven of the 13 (53.8%) felt that CAM was neither helpful nor harmful in the treatment of their cancer. Of the remainder, 5 patients (38.5%) said that CAM was at least benefi cial, and 1 (7.7%) believed it to be curative.
Seven of the 13 users (53.8%) had discussed CAM with a physician prior to participating in the survey. Most of them viewed their physician's response as supportive, although none of these physicians had provided any additional information about CAM during the encounters.
Discussion
The prevalence of CAM use among oncology patients in large series has been reported to range from 40 to 90%. [3] [4] [5] [6] [7] In studies of head and neck cancer patients exclusively, CAM use has been reported by 20 to 90% of patients. 8,10,11 The 6.1% prevalence of CAM use in our study is signifi cantly lower than what has been reported in most previous investigations, although Talmi et al found a nearly identical rate (6.3%) in their series of head and neck oncology patients. 9 Those authors suggested that close patient follow-up and a strong patient-caregiver relationship could have been responsible for the limited use of CAM in their study. They also contended that tumors of the head and neck are less functionally debilitating than other cancers, and they thus speculated that this might explain their fi ndings.
While these may indeed be valid suppositions, there appear to be other factors involved-particularly when one considers that reported CAM use has been higher in older studies than in more recent ones. One possible reason for this may be that treatment paradigms have changed in recent years to include a number of adjuvant and organ-sparing therapies. Examples include the addition of chemotherapy to radiation therapy in the postoperative setting, the use of chemoradiation for organ preservation, and the emergence of novel therapies such as cetuximab. Such treatments are relatively well tolerated, and they have been shown to result in equal or better outcomes than more traditional protocols. Furthermore, these treatments are often used in a stepwise fashion for persistent or recurrent disease, which allows the head and neck oncology team to continue providing therapeutic options and, just as important, hope. The widespread availability of these "conventional alternatives" in recent years may indeed be responsible for the apparent decrease in CAM use by head and neck cancer patients.
Regardless of the overall prevalence of CAM use, it is apparent that biologically active substances are the most popular of the CAM modalities, based on the results of this and other investigations of patients with head and neck cancer. The vast majority of these treatments are unproven and are not subject to the scrutiny of the federal Food and Drug Administration. Nevertheless, nearly 40% of our patients perceived at least some benefi t of CAM in the treatment of their head and neck cancer. Certainly one could argue that patients may have a bias of expectation and that the design of our study precluded any in-depth analysis of these patients' claims. However, we should not dismiss their claims simply because the potential for bias exists, particularly when one considers that each of these patients was using CAM as a cancerdirected therapy rather than for the improvement of general health and well-being. Indeed, 1 patient even felt that CAM was curative. This particular individual noted that despite having undergone conventional therapy, he did not believe that he could be cured without CAM. He said he used six different biologically active substances, including fi sh oils, wheat germ, glutamine, marijuana, and Maitake mushrooms. It is interesting that Maitake extracts are thought to be immunomodulators and that they have shown potential as anticancer agents. 12, 13 However, they have not been studied in the context of squamous cell carcinomas of the head and neck. The role to which Maitake extracts and the other substances played in this patient's perceived cure is unclear, but they might merit further investigation. Even though no patient in our series reported any adverse effects of CAM treatments, it should be remembered that the use of such substances may have serious consequences-from both the direct pharmacologic effects of the agents and their interactions with standard radio-, chemo-, and surgical therapies. For instance, commonly used CAM treatments such as garlic, ginkgo biloba, and vitamin E may predispose patients to bleeding. [14] [15] [16] An example of the indirect effects of CAM may be seen in patients who take large doses of antioxidant vitamins and minerals. While these agents play a vital role in free-radical scavenging and DNA repair (targets of their anticancer effects), they may counteract the effects of radiotherapy. Even at recommended doses, supplemental antioxidant use has been associated with increased local recurrence rates among patients treated for head and neck cancers. 17 In order to prevent such ill effects, we must fi rst identify the patients who are at risk of incurring them. The best way of accomplishing this is to elicit a CAM history during every patient encounter. Of course, this will not always be an easy task. Indeed, the 53.8% disclosure rate reported in our survey is consistent with those of other reports. 2, 3, 10 For a variety of reasons, many patients do not volunteer information about CAM use to their physicians. They may be embarrassed; they may be afraid of disappointing their physician; they may not recognize the potential risk of the treatments they are using; or they may simply not even realize that what they are using can be considered a "medicine." For these reasons, we advocate explaining CAM to patients and then taking a highly specifi c history with attention paid to the types, doses, and sources of therapies, as well as the patient's goals and expectations of CAM as a cancer treatment.
While it is imperative that we disclose to our patients any bias that we may have in support of or opposition to CAM, we must also be cautious to avoid passing judgment on them for pursuing CAM as part of their cancer treatment. Doing so may irreparably damage a patient's trust in the physician and adversely affect future interactions and treatment plans.
We acknowledge several limitations to our study. First, the 6.1% rate of CAM use represents a point prevalence from a single practice. As such, the group included newly diagnosed patients, those who were currently undergoing treatment, those who were disease-free after treatment, and those with recurrent and/or persistent disease. Consequently, the population of patients is somewhat heterogeneous with respect to stage and chronicity of disease. As a result, the language of the survey was general enough so that it would be applicable to patients fi tting any of these circumstances. Also, because of the anonymous nature of the survey, each patient's precise cancer stage could not be ascertained with certainty. We do acknowledge that both initial stage and "curability" of disease by conventional means might have played a role in a patient's decision to pursue complementary therapies-that is, patients who had more advanced disease might have been more likely to use CAM in an effort to improve their chances of cure. A follow-up study is needed to evaluate the relationship between CAM use and variables such as stage, chronicity of disease, previous treatments, and patient race/ethnicity and socioeconomic status. To best achieve this goal, a more inclusive and validated survey will need to be developed. The aim of our study was to evaluate overall prevalence among a representative sample of our head and neck cancer patient population. We feel that we achieved this goal, but we recognize that the potential for bias does exist with this methodology.
Cultural differences may also affect a patient's decision to use CAM. We did not collect any data regarding race or ethnicity in this survey. We do acknowledge that this is another potential source of selection bias and that it somewhat limits our ability to generalize our results to other populations of head and neck cancer patients.
In conclusion, we found that CAM use was not widely prevalent (6.1% of respondents) among our series of 213 patients. When this fi nding is taken in the context of reports in the recent literature, we might surmise that CAM use among head and neck cancer patients is on the decline. It is thought that the lower prevalence rates may in part be attributed to the widespread availability and use of "conventional alternatives" in the multidisciplinary management of head and neck cancers. Additional studies are needed to support or refute this theory. In such an effort, investigators would ideally control for disease stage and specifi c conventional therapies employed.
Although the numbers of patients who use CAM for head and neck cancer may be decreasing, we must remember that among those who do use it, most take biologically active substances. These therapies are often unproven and untested, and they may adversely affect treatment and outcomes. Therefore, physicians must elicit a highly specifi c history from all head and neck cancer patients, keeping in mind that approximately half of them will not disclose CAM use without being asked. There must also be a willingness among physicianscientists to evaluate the effi cacy and potential side effects of unconventional cancer therapies through controlled experiments and clinical trials.
While we may harbor our own biases for or against unconventional therapies, we must at all times respect patient autonomy when patients decide to pursue CAM as a component of their cancer treatment. At the same time, we should be prepared to provide them with objective information and educational resources so that they can make a more well-informed decision.
